Alnylam Pharmaceuticals, Inc. (ALNY) Shares Sold by Schwab Charles Investment Management Inc.

Schwab Charles Investment Management Inc. lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 182,509 shares of the biopharmaceutical company’s stock after selling 10,033 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $9,354,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of ALNY. FMR LLC raised its stake in shares of Alnylam Pharmaceuticals by 0.3% in the first quarter. FMR LLC now owns 12,907,883 shares of the biopharmaceutical company’s stock worth $661,530,000 after buying an additional 35,803 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Alnylam Pharmaceuticals by 0.3% in the first quarter. Wellington Management Group LLP now owns 12,041,179 shares of the biopharmaceutical company’s stock worth $617,111,000 after buying an additional 31,208 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 3.7% in the first quarter. Vanguard Group Inc. now owns 5,660,213 shares of the biopharmaceutical company’s stock worth $290,086,000 after buying an additional 200,890 shares during the last quarter. BlackRock Inc. raised its stake in shares of Alnylam Pharmaceuticals by 34,755.2% in the first quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock worth $243,242,000 after buying an additional 4,732,617 shares during the last quarter. Finally, Baillie Gifford & Co. raised its stake in shares of Alnylam Pharmaceuticals by 0.5% in the first quarter. Baillie Gifford & Co. now owns 3,334,511 shares of the biopharmaceutical company’s stock worth $170,894,000 after buying an additional 16,489 shares during the last quarter. Institutional investors and hedge funds own 89.00% of the company’s stock.

Alnylam Pharmaceuticals, Inc. (ALNY) opened at 81.01 on Wednesday. The stock has a 50 day moving average of $78.83 and a 200-day moving average of $58.26. Alnylam Pharmaceuticals, Inc. has a 12 month low of $31.38 and a 12 month high of $86.92. The company’s market cap is $6.98 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by $0.03. The company had revenue of $19 million for the quarter, compared to the consensus estimate of $22.91 million. Alnylam Pharmaceuticals had a negative net margin of 705.11% and a negative return on equity of 42.90%. Alnylam Pharmaceuticals’s quarterly revenue was up 160.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.21) EPS. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post ($5.23) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Alnylam Pharmaceuticals, Inc. (ALNY) Shares Sold by Schwab Charles Investment Management Inc.” was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://transcriptdaily.com/2017/07/26/alnylam-pharmaceuticals-inc-alny-shares-sold-by-schwab-charles-investment-management-inc.html.

A number of equities research analysts recently commented on ALNY shares. Cowen and Company restated a “buy” rating and set a $100.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, July 11th. Vetr downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 target price for the company. in a research report on Monday, May 15th. Piper Jaffray Companies set a $118.00 target price on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, May 15th. Credit Suisse Group raised their target price on shares of Alnylam Pharmaceuticals from $90.00 to $96.00 and gave the company an “outperform” rating in a research report on Tuesday, June 27th. Finally, Chardan Capital decreased their target price on shares of Alnylam Pharmaceuticals from $110.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, May 15th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $78.83.

In related news, major shareholder Sanofi purchased 297,501 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, May 31st. The stock was bought at an average price of $71.87 per share, for a total transaction of $21,381,396.87. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Akshay Vaishnaw sold 11,000 shares of the stock in a transaction dated Tuesday, May 23rd. The shares were sold at an average price of $75.00, for a total transaction of $825,000.00. Following the transaction, the executive vice president now owns 21,297 shares of the company’s stock, valued at approximately $1,597,275. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 64,125 shares of company stock valued at $4,325,000. 4.30% of the stock is owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply